Cancer Intelligence Limited - Period Ending 2018-12-31

Cancer Intelligence Limited - Period Ending 2018-12-31


Cancer Intelligence Limited 04595666 false 2018-01-01 2018-12-31 2018-12-31 The principal activity of the company is the provision of medical research and consultancy services. The company also publishes an online cancer journal for the European Institute of Oncology. The journal publishes oncology research, news and interviews with cancer experts Digita Accounts Production Advanced 6.24.8820.0 Software true false 04595666 2018-01-01 2018-12-31 04595666 2018-12-31 04595666 bus:OrdinaryShareClass1 2018-12-31 04595666 bus:OrdinaryShareClass2 2018-12-31 04595666 core:RetainedEarningsAccumulatedLosses 2018-12-31 04595666 core:ShareCapital 2018-12-31 04595666 core:CurrentFinancialInstruments 2018-12-31 04595666 core:CurrentFinancialInstruments core:WithinOneYear 2018-12-31 04595666 core:Non-currentFinancialInstruments 2018-12-31 04595666 core:Non-currentFinancialInstruments core:AfterOneYear 2018-12-31 04595666 core:FurnitureFittingsToolsEquipment 2018-12-31 04595666 core:LandBuildings 2018-12-31 04595666 1 2018-12-31 04595666 2 2018-12-31 04595666 3 2018-12-31 04595666 bus:SmallEntities 2018-01-01 2018-12-31 04595666 bus:AuditExemptWithAccountantsReport 2018-01-01 2018-12-31 04595666 bus:FullAccounts 2018-01-01 2018-12-31 04595666 bus:SmallCompaniesRegimeForAccounts 2018-01-01 2018-12-31 04595666 bus:RegisteredOffice 2018-01-01 2018-12-31 04595666 bus:CompanySecretary1 2018-01-01 2018-12-31 04595666 bus:Director1 2018-01-01 2018-12-31 04595666 bus:Director2 2018-01-01 2018-12-31 04595666 bus:OrdinaryShareClass1 2018-01-01 2018-12-31 04595666 bus:OrdinaryShareClass2 2018-01-01 2018-12-31 04595666 bus:PrivateLimitedCompanyLtd 2018-01-01 2018-12-31 04595666 core:FurnitureFittingsToolsEquipment 2018-01-01 2018-12-31 04595666 core:LandBuildings 2018-01-01 2018-12-31 04595666 core:OfficeEquipment 2018-01-01 2018-12-31 04595666 1 2018-01-01 2018-12-31 04595666 2 2018-01-01 2018-12-31 04595666 3 2018-01-01 2018-12-31 04595666 countries:AllCountries 2018-01-01 2018-12-31 04595666 2017-12-31 04595666 core:CostValuation 2017-12-31 04595666 core:FurnitureFittingsToolsEquipment 2017-12-31 04595666 core:LandBuildings 2017-12-31 04595666 2017-01-01 2017-12-31 04595666 2017-12-31 04595666 bus:OrdinaryShareClass1 2017-12-31 04595666 bus:OrdinaryShareClass2 2017-12-31 04595666 core:RetainedEarningsAccumulatedLosses 2017-12-31 04595666 core:ShareCapital 2017-12-31 04595666 core:CurrentFinancialInstruments 2017-12-31 04595666 core:CurrentFinancialInstruments core:WithinOneYear 2017-12-31 04595666 core:Non-currentFinancialInstruments 2017-12-31 04595666 core:Non-currentFinancialInstruments core:AfterOneYear 2017-12-31 04595666 core:FurnitureFittingsToolsEquipment 2017-12-31 04595666 core:LandBuildings 2017-12-31 04595666 1 2017-12-31 04595666 2 2017-12-31 04595666 3 2017-12-31 iso4217:GBP xbrli:pure xbrli:shares

Registration number: 04595666

Cancer Intelligence Limited

Annual Report and Unaudited Financial Statements

for the Year Ended 31 December 2018

PRWS (Bristol) Limited
Chartered Certified Accountants
11 Alma Vale Road
Clifton
Bristol
BS8 2HL

 

Cancer Intelligence Limited

Contents

Company Information

1

Balance Sheet

2 to 3

Notes to the Financial Statements

4 to 10

 

Cancer Intelligence Limited

Company Information

Directors

Prof J Gordon McVie

Ms Susi Burke

Company secretary

Mr Mark Longbottom

Registered office

11 Alma Vale Road
Clifton
Bristol
BS8 2HL

Accountants

PRWS (Bristol) Limited
Chartered Certified Accountants
11 Alma Vale Road
Clifton
Bristol
BS8 2HL

 

Cancer Intelligence Limited

(Registration number: 04595666)
Balance Sheet as at 31 December 2018

Note

2018
£

2017
£

Fixed assets

 

Tangible assets

4

528,779

543,591

Investments

5

100

100

 

528,879

543,691

Current assets

 

Debtors

6

86,229

286,267

Cash at bank and in hand

 

10,212

181,452

 

96,441

467,719

Creditors: Amounts falling due within one year

7

(262,606)

(477,967)

Net current liabilities

 

(166,165)

(10,248)

Total assets less current liabilities

 

362,714

533,443

Creditors: Amounts falling due after more than one year

7

(55,920)

(189,284)

Net assets

 

306,794

344,159

Capital and reserves

 

Called up share capital

8

12

12

Profit and loss account

306,782

344,147

Total equity

 

306,794

344,159

For the financial year ending 31 December 2018 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime and the option not to file the Profit and Loss Account has been taken.

 

Cancer Intelligence Limited

(Registration number: 04595666)
Balance Sheet as at 31 December 2018

Approved and authorised by the Board on 19 August 2019 and signed on its behalf by:
 

.........................................

Prof J Gordon McVie
Director

 

Cancer Intelligence Limited

Notes to the Financial Statements for the Year Ended 31 December 2018

1

General information

The company is a private company limited by share capital, incorporated in Engalnd & Wales.

The address of its registered office is:
11 Alma Vale Road
Clifton
Bristol
BS8 2HL
United Kingdom

The principal place of business is:
13 King Square Avenue
Bristol
BS2 8HU
United Kingdom

These financial statements were authorised for issue by the Board on 19 August 2019.

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A - 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006.

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Tax

The tax expense for the period comprises current tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

 

Cancer Intelligence Limited

Notes to the Financial Statements for the Year Ended 31 December 2018

Tangible assets

Tangible assets are stated in the statement of financial position at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Office equipment

20% on cost on a reducing balance basis

Leasehold buildings

0.1% and 0.83% reducing balance basis

Business combinations

Business combinations are accounted for using the purchase method. The consideration for each acquisition is measured at the aggregate of the fair values at acquisition date of assets given, liabilities incurred or assumed, and equity instruments issued by the group in exchange for control of the acquired, plus any costs directly attributable to the business combination. When a business combination agreement provides for an adjustment to the cost of the combination contingent on future events, the group includes the estimated amount of that adjustment in the cost of the combination at the acquisition date if the adjustment is probable and can be measured reliably.

Investments

Investments in equity shares which are publicly traded or where the fair value can be measured reliably are initially measured at fair value, with changes in fair value recognised in profit or loss. Investments in equity shares which are not publicly traded and where fair value cannot be measured reliably are measured at cost less impairment.


Interest income on debt securities, where applicable, is recognised in income using the effective interest method. Dividends on equity securities are recognised in income when receivable.

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

 

Cancer Intelligence Limited

Notes to the Financial Statements for the Year Ended 31 December 2018

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Borrowings

Interest-bearing borrowings are initially recorded at fair value, net of transaction costs. Interest-bearing borrowings are subsequently carried at amortised cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognised as a charge to the Profit and Loss Account over the period of the relevant borrowing.

Interest expense is recognised on the basis of the effective interest method and is included in interest payable and similar charges.

Borrowings are classified as current liabilities unless the company has an unconditional right to defer settlement of the liability for at least twelve months after the reporting date.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Dividends

Dividend distribution to the company’s shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.

Defined contribution pension obligation

A defined contribution plan is a pension plan under which fixed contributions are paid into a pension fund and the company has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.

Contributions to defined contribution plans are recognised as employee benefit expense when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.

3

Staff numbers

The average number of persons employed by the company (including directors) during the year, was 21 (2017 - 21).

 

Cancer Intelligence Limited

Notes to the Financial Statements for the Year Ended 31 December 2018

4

Tangible assets

Land and buildings
£

Furniture, fittings and equipment
 £

Total
£

Cost or valuation

At 1 January 2018

490,928

113,458

604,386

Additions

-

580

580

Disposals

-

(8,445)

(8,445)

At 31 December 2018

490,928

105,593

596,521

Depreciation

At 1 January 2018

6,101

54,693

60,794

Charge for the year

1,104

11,859

12,963

Eliminated on disposal

-

(6,015)

(6,015)

At 31 December 2018

7,205

60,537

67,742

Carrying amount

At 31 December 2018

483,723

45,056

528,779

At 31 December 2017

484,827

58,764

543,591

Included within the net book value of land and buildings above is £483,723 (2017 - £484,827) in respect of long leasehold land and buildings.
 

5

Investments

2018
£

2017
£

Investments in subsidiaries

100

100

Subsidiaries

£

Cost or valuation

At 1 January 2018

100

Provision

Carrying amount

At 31 December 2018

100

At 31 December 2017

100

 

Cancer Intelligence Limited

Notes to the Financial Statements for the Year Ended 31 December 2018

6

Debtors

Note

2018
£

2017
£

Trade debtors

 

41,395

138,920

Amounts owed by group undertakings and undertakings in which the company has a participating interest

11

327

327

Prepayments

 

-

11,792

Other debtors

 

44,507

135,228

 

86,229

286,267

7

Creditors

Creditors: amounts falling due within one year

Note

2018
£

2017
£

Due within one year

 

Bank loans and overdrafts

9

167,926

36,504

Trade creditors

 

65,845

157,720

Taxation and social security

 

766

12,704

Accruals and deferred income

 

15,359

257,208

Other creditors

 

12,710

13,831

 

262,606

477,967

Creditors: amounts falling due after more than one year

Note

2018
£

2017
£

Due after one year

 

Loans and borrowings

9

55,920

189,284

8

Share capital

Allotted, called up and fully paid shares

 

Cancer Intelligence Limited

Notes to the Financial Statements for the Year Ended 31 December 2018

 

2018

2017

 

No.

£

No.

£

Ordinary shares of £1 each

11

11

11

11

Ordinary B share of £1 each

1

1

1

1

 

12

12

12

12

9

Loans and borrowings

2018
£

2017
£

Non-current loans and borrowings

Bank borrowings

55,920

189,284

2018
£

2017
£

Current loans and borrowings

Bank borrowings

98,612

23,980

Other borrowings

69,314

12,524

167,926

36,504

Bank borrowings

Bank loan is denominated in GBP with a nominal interest rate of 4.68%, and the final instalment is due on 31 January 2019. The carrying amount at year end is £64,743 (2017 - £72,491).

Bank loan is denominated in GBP with a nominal interest rate of 5.33%, and the final instalment is due on 31 January 2019. The carrying amount at year end is £26,369 (2017 - £37,567).

Bank Loan is denominated in GBP with a nominal interest rate of 3%, and the final instalment is due on 25 October 2025. The carrying amount at year end is £63,420 (2017 - £71,422).

Bank loans are secured against the the company property at King Square Avenue

10

Dividends

   

2018

 

2017

   

£

 

£

Interim dividend of £26,688.00 (2017 - £50,445.00) per ordinary share

 

26,688

 

50,445

 

Cancer Intelligence Limited

Notes to the Financial Statements for the Year Ended 31 December 2018

11

Related party transactions

Directors' remuneration

The directors' remuneration for the year was as follows:

2018
£

2017
£

Remuneration

4,848

8,136

Contributions paid to money purchase schemes

20,946

46,555

25,794

54,691